Bromocriptine Monotherapy Overcomes Prostate Cancer Chemoresistance in Preclinical Models

Using a two-tier phenotypic screening platform, researchers identified bromocriptine mesylate as a potent and selective inhibitor of chemoresistant prostate cancer cells.